Recruiting

TVT ABBREVO®

Sponsor:

Ethicon, Inc.

Code:

NCT04829357

Conditions

Stress Urinary Incontinence

Eligibility Criteria

Sex: Female

Age: 21+

Healthy Volunteers: Not accepted

Interventions

Intervention

Study Details

Brief summary:

The objective of this single arm, post market, clinical study is to evaluate the performance of Gynecare TVT ABBREVO® Continence System in women undergoing Mid-urethral sling surgery for Stress Urinary Incontinence (SUI).

Conditions

Stress Urinary Incontinence

Study ID

NCT04829357

Start date

Sep 9, 2021

Status verified date

Jul, 2026

Completion date

Dec 31, 2038

Anticipated

Primary completion date

Dec 31, 2033

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 21+

Healthy Volunteers: Not accepted

Inclusion Criteria:

Subjects who satisfy all of the following criteria will be considered eligible for enrollment in this study:

1. Stress urinary incontinence symptoms
2. Diagnostic evaluation, a positive cough stress rest, to confirm diagnosis of stress urinary incontinence.
3. Female subjects ≥ 21 years of age requiring treatment of SUI
4. Desired surgical correction of stress urinary incontinence using synthetic sub-urethral vaginal slings
5. Planned surgery for primary stress incontinence without concomitant prolapse surgery
6. Patient able and willing to participate in follow-up
7. Subject or authorized representative has signed the approved informed consent

Exclusion Criteria

Subjects meeting any of the following criteria will be considered not eligible for enrollment in this study:

1. Physical or psychological condition which would impair study participation or are unwilling or unable to participate in all required study visits and are unable to complete the questionnaires
2. Any pre-operative or intra-operative findings identified by the surgeon that may preclude the use of study product
3. History of previous synthetic, biologic or fascial sub-urethral sling
4. Pregnancy or plans for future pregnancy
5. History of bleeding diathesis or current anti-coagulation therapy which cannot be suspended peri-operatively according to site's standard practice.
6. Current genitourinary fistula or urethral diverticulum
7. Reversible cause of incontinence (i.e. drug effect)
8. Contraindication to surgery

Study Design

Enrollment

195 participants

Anticipated

Interventions and Outcome Measures

Interventions

Intervention

There is no intervention, beyond necessary clinical care, in this study. The surgical procedures being performed within the study are identical to the surgical procedures the subjects would receive as part of SOC.

Primary outcome measure

  • Cough Stress Test (CST) Assessment Change [ Time Frame: Post-surgery through study completion, approximately 5-10 yrs ]

Central Contacts and Locations

Central contacts

Locations

Institute for Female Pelvic Medicine

Recruiting

North Wales, Pennsylvania, United States, 19454

More Information

Sponsor

Ethicon, Inc.

Last update posted

Jul 6, 2026

Last verified

Jul, 2026

Keywords

  • Gynecare TVT ABBREVO® Continence System
  • SUI

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Ethicon, Inc. on 2026-07-06.